Last Updated on October 17, 2024 by The Health Master
USFDA approves Eli Lilly’s Trulicity to reduce cardiovascular risks in type 2 diabetic patients
(Reuters) – Eli Lilly and Co said on the U.S. Food and Drug Administration (USFDA) has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.
The approval makes Trulicity the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease, the company said in a statement.
Also read: Zydus gets USFDA approval for generic Canasa
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
